Brief: Wave Life Sciences Plans To Have Five Galnac-RNA Editing Or GalNAc-siRNA Programs In Clinic By 2026
Oct 30 (Reuters) - WAVE Life Sciences Ltd WVE.O :
* WAVE LIFE SCIENCES LTD: PLANS TO HAVE FIVE GALNAC-RNA
EDITING OR
GALNAC-SIRNA PROGRAMS IN CLINIC BY 2026
* WAVE LIFE SCIENCES LTD: WVE-007 (INHBE GALNAC-SIRNA FOR
OBESITY)
IS ON TRACK TO INITIATE A CLINICAL TRIAL IN 1Q 2025
* WAVE LIFE SCIENCES: NEW PRECLINICAL DATA IN DIET INDUCED
OBESE
(DIO) MICE DEMONSTRATE POTENTIAL OF WVE-007 TO BE USED ACROSS
TREATMENT CONTINUUM
Source text: ID:nGNX9pk720
Further company coverage: WVE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Wave Life Sciences
See all newsWave Life Sciences Ltd Reports Results For The Quarter Ended June 30: Earnings Summary
Wave Life Sciences Ltd Expected To Post A Loss Of 31 Cents A Share: Earnings Preview
Wave Life Sciences Q1 revenue jumps, beats analyst estimates
Brief: Wave Life Sciences Announces Hearing On Proposed Redomiciliation To The United States
Brief: Wave Life Sciences Announces Proposed Redomiciliation To The United States